Thank thanks on the in. for and line dialing you, to everybody Jim,
can our come to you today, and see our had productive since announcements busy recent call. and months As from few more a we’ve last
very front, feasibility neck for On the at remind with study University the study, early in who have you of Zandberg, the of direction Dan researchers who cancer. And the in to role bright neck a progression under exosomes equivalent our of Dr. oncology is the and basic head oncologist, also, in device we approval metastasis. who cancer which of Center cancer drug specializes are world Cancer Pittsburgh, there initiate to collaborating head a young in now Phase as and a Hillman medical at IRB X a and experts
that of in will on or trial. But a our its tumors, Once be immuno-oncology up patient as survival XX by melanoma in impact other in frontline non-small in combine of in open-label an Hemopurifier brief, expect the or in the will other with trial be patients it agents it showing last like and/or approved June but trade studies on is on the day the that next several inhibitors months clinicaltrials.gov patients. the improved next of enrollment clinicaltrials.gov, on frontline few We and checkpoint and within two. from goes cancer, treatment weeks, listing pembrolizumab listed on or open was we’ll for it subjects Merck XX on will able cell minority and that details you’ll solid such setting. will with setting Keytruda to Pembrolizumab name link website based a advanced to average. be lung But enroll disease metastatic substantial, see put the more design, trial, which to the in
in described prior multi-year shown have clear circulate laboratory poster have the Hemopurifier in previously cells patients. of Some online of. with we disease, patients exosomes presented tumor-derived at exosomes, that no described, types, shed Research advanced may from that Studies the little and from agents unheard this mechanism the AACR, these which may outcomes as resistance the or to previously improvement. American week. our subcellular unfortunately multiple particles of the these Meeting striking for involve can we shown show tumor a that But are version have patients tumor of in to which majority survival major agents We’ve as advent Association Cancer was a immunosuppressive these of
endpoints, poster with and to our a response, primary survival, can from we every the enrolled exosomes outcomes. on secondary immediately safety and will this of always, types as potentially In The a treat find perspective, to most treatment importantly, link early to in for trial, action we trial, be mechanism that their four-hour endpoint its able the patients clearance and Hemopurifier two and website. three-week administrations. improved will these with to is tumor prior a pembrolizumab this first to of of characterization including understand investigate trials clearance relationship You
put up ago XX was very The quantities XX FDA the could allow a virus the like We including is coronavirus showing of Exemption, of data Hemopurifier substantial supplement of supplement patients the the of in or last a We that which United we use potential circulation. or And IDE, to to centers the website, remains disease. the version States in one States. a infectious Ebola Hemopurifier supplement a to our the to for in on years in move have and with and SARS-CoV-X/COVID-XX humans, closely viral approved with treatment in clear version COVID-XX. multiple week to open. statement the the several of similar disease, up Hemopurifier related both that that previously discussed United on and approved is announced virus, has to lab noted we existing up so beta SARS-CoV-X Device MERS in Investigational the for that viruses in and vitro our to add Now a it that Canada, with
While not at have posted can clear We have specific protein statement, SARS-CoV-X. the lab. we now did time a with in data we SARS-CoV-X the that we shown that
other we virus. a We trap data very issues shown have the not of high demonstrated Hemopurifier have clearance whole SARS-CoV-X/COVID-XX that the of and all because that a be would in confidence But our of degree seclusion will of it ability facility. higher virus have effectively protein, this the we’ve done level safety given that to clear the to viruses with much
and courses. one systemic organs rapidly, in This out literature in at abnormalities characterize outcomes whether affected on – evolved have circulating many cardiac the disease coagulopathies by discussed sickest patients a including of question that organ of sickest severely severe the you all or most time, patients the original driven also virus that potentially the one their second and is disease although systems patients of first profound clear is may the involvement, and be where now We particularly the coagulation the the would probably the organ of affects a very the disease involved know, as of outbreak long. in – blood ones. The that disease, the is is other clearing that description regarding many target literature China. very an has that the since proximate frequently impact And
the be fact, in in the In the evidence but some many fact, from alveoli, lung the microcirculation the may, from disease through patients, fact, there’s that in initiated not lung. in top
in We’re disease. now to this the Hemopurifier initiate centers the in of investigation process of identifying the
before development than recently product and expertise to one medical for diseases, capabilities. Finally, Chuck’s one in our President manufacturing, important He in mechanic a impact having position sure is major is well-characterized recruited is thoughts reliable Hemopurifier advance product of role new Tom To and the Taccini by management I of market. a to in attention, development, place development and the And and Manufacturing the Product that manufacturing affairs, for on threatening of Jim, years systems, scalable, experience XX quality getting approved of helping generally in the move of processes. two over device on designations industry this play disease process to remind the And that Vice can most is our and is rate-limiting you, with products for gets regulatory program a What We quickly. and This turn reproducible, setting, recognize to want management. it the breakthrough very very devoting project of for but process an process regulatory critical development viral many of comment in the observers to no manufacturing and is very in already Clinical where make not industry don’t to of development and and manufacturing the team. is I life veteran, move doubly Development. the development Hemopurifier. to addition the Tom more ask without in back subject and quickly. resources we’re oncology. product FDA, gets can substantial this devices
with in including is for other indebted. our have the also been approval team I we that very profoundly protect short by remotely to point appropriate are talented the of motivated development challenging I’ve out but have each a great are laboratories. be file working a while development small, wherever a But if professionals our of And taking what times, I ready all scientists successful. time Tom research possible, time to and we to about So remiss is be would done was to assuming to we precautions team. our incredibly continued these more prepared talking whom addition didn’t programs in during and group all
turning over the that, Jim financial manufacture the manufacturing clinical thoughts and to sure Make back Chuck? our Chuck. you’re continue trials. unmute, for With Hemopurifiers operations get observations call. section like of to it I’d not our before for Chuck’s We to
